G investigators who collected information and cared for individuals participating in the study: Purvi R Bhagat, M J Western Regional Institute of Ophthalmology, Civil Hospital, Ahmedabad; Tejaswini Prasad Walimbe, Walimbe Eye Clinic, Pune; K Sodimalla, PBMA’s H.V. Desai Eye Hospital, Pune; Nilesh V Parekh, Department of Ophthalmology, Government Healthcare College and Sir Takhtsinhji Hospital, Bhavnagar; Pradeep L Jain, Netraseva, Jalna; Ganesh Venkata Raman, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Coimbatore; Chandrima Paul, B B Eye Foundation, Kolkata; Sumit Choudhury, Eye Care and Study Centre, Kolkata; Surinder S Pandav, Sophisticated Eye Centre, Postgraduate Institute of Healthcare Education and Research, Chandigarh; Sushma Tejwani, Narayana Nethralaya Super Speciality Eye Hospital, Bangalore; Sonika Shah, Navkar Eye Clinic, Nashik; Yogesh Shah, Netra Mandir, Mumbai; R Ramakrishnan, Aravind Eye Hospital and Postgraduate Institute of Ophthalmology, Tirunelveli Junction; Sonal Shamik Ambatkar, Shaureen Sophisticated Eye Care, Nagpur; Ashish Thool, Netranjali Centre for Advanced Eye Care, Nagpur; Rekha Raju Khandelwal, NKP Salve Institute of Healthcare Sciences, Nagpur, India.DisclosurePB, KS, CP, SSP, GVR, and RR have received analysis grants and nonfinancial support from Sun Pharma Advanced Research1. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship in between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429-440. two. Kastelan S, Tomic M, Metez SK, Salopek-Rabatic J. How ocular surface disease impacts the glaucoma treatment outcome. Biomed Res Int. 2013;2013:696328. three. Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of readily available drug treatment options. Ther Adv Chronic Dis. 2014;5:30-43. 4. Dietlein TS, Hermann MM, Jordan JF. The health-related and surgical treatment of glaucoma. Dtsch Arztebl Int. 2009;106:597-605. five. Stewart RH, Kimbrough RL, Ward RL. Betaxolol vs timolol. A sixmonth double-blind comparison. Arch Ophthalmol. 1986;104:46-48. six. Zimmerman TJ, Kaufman HE. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma.1398496-40-6 Formula Arch Ophthalmol.4-Oxotetrahydrofuran-3-carbonitrile Price 1977;95:601-604. 7. Toris CB, Gabelt BT, Kaufman PL.PMID:24563649 Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv Ophthalmol. 2008;53 Suppl 1:S107-S120. eight. Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015 versus latanoprost 0.005 eye drops in open-angle glaucoma and ocular hypertension: 24-month benefits of a randomized, doublemasked phase III study. Acta Ophthalmol. 2010;88:12-19. 9. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of key openangle glaucoma. Arch Ophthalmol. 2002;120:701-713. ten. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandintimolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012;22:5-18. 11. Xalatan? Package insert. New York, NY, USA: Pfizer Inc; 2011. 12. Timoptic? Package insert. Whitehouse Station, NJ, USA: Merck Co; 2005. 13. Costa VP, Moreira H, Paolera MD, de Moraes Silva MR. Efficacy and security of travoprost 0.004 /timolol 0.five fixed mixture as transition therapy in sufferers previously on prostaglandin analog monotherapy. Clin Ophthalmol. 2012;6:699-706. 14. Higginbotham EJ, F.